Chemotherapy with or without immunotherapy for advanced rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests whether adding an immunotherapy drug (pucotenlimab) to standard chemotherapy (CAPOX) before surgery helps treat locally advanced rectal cancer better. The goal is to shrink tumors and improve survival while preserving bowel function when possible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years
- Rectal cancer confirmed by biopsy, with tumor within 12 cm of the anus
- Advanced stage cancer (spread to lymph nodes or deeper tissue layers) but no distant spread
- Healthy bone marrow and organ function (liver, kidneys, heart)
- No prior cancer treatment (surgery, chemotherapy, or radiation)
- Willingness to provide blood, tissue samples, and comply with study visits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two chemotherapy combinations given before surgery for low rectal cancer. One group gets a standard chemo pill (CAPOX), while the other gets a more intense combination of three chemo drugs plus an immunotherapy drug (PD-1 inhibitor) to see which approach works better at shrinking tumors.
This trial tests a combination of radiation, immunotherapy (a drug that helps your immune system fight cancer), and chemotherapy before surgery for high-risk rectal cancer that has not spread. It aims to improve the chance of shrinking or eliminating the tumor before surgery.
This trial tests adding an immunotherapy drug (pucotenlimab) to standard radiation and chemotherapy before surgery for locally advanced rectal cancer. The goal is to see if this combination can shrink the tumor more effectively and improve outcomes.
This Phase 2 study tests penpulimab (an immunotherapy medicine) given with CAPEOX chemotherapy before surgery for rectal cancer that is “MSS” (not the mismatch-repair type). It aims to shrink the tumor and improve outcomes by treating before the operation.
This study tests a combination of radiation therapy, chemotherapy drugs (capecitabine and oxaliplatin), and two types of immunotherapy (a PD-1 blocker and IL-2) for locally advanced rectal cancer. The goal is to see if this combination helps shrink tumors and improve outcomes before surgery.
This trial tests if adding immunotherapy to standard chemotherapy and radiation before surgery helps shrink high-risk rectal cancer and prevent it from coming back. You may be a good fit if you have a specific type of advanced rectal cancer that hasn't spread to other parts of your body.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.